Multi-center clinical study to investigate the ratio of patients who have achieved Complete Molecular Response (CMR) with nilotinib treatment, among patients with chronic myelogenous leukemia in chronic phase who achieved Major Molecular Response (MMR) with imatinib treatment.

Trial Profile

Multi-center clinical study to investigate the ratio of patients who have achieved Complete Molecular Response (CMR) with nilotinib treatment, among patients with chronic myelogenous leukemia in chronic phase who achieved Major Molecular Response (MMR) with imatinib treatment.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top